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Background: The aim of the study was to identify the incidence and the predictors of recurrence after curative
resection and the clinical significance of epithelial-mesenchymal transition (EMT) and stem cell-like phenotypes in
gastric cancer.
Methods: In a total of 1,463 patients that underwent curative resection for gastric cancer between January 2001
and January 2008 at Drum Tower Hospital, 402 (27.5%) experienced recurrence. They were divided into early
recurrence (within two years) and late recurrence (more than two years). The clinicopathological characteristics,
including five EMT-related proteins (Snail-1, ZEB-1, E-cadherin, vimentin, and β-catenin) and the gastric cancer stem
cell markers CD44 and CD54, therapeutic modalities, survival time after recurrence, and recurrence patterns were
compared between the two groups.
Results: Loss of E-cadherin expression and aberrant expression of vimentin and the known gastric cancer stem cell
maker CD44 were significantly associated with aggressive clinicopathologic features. Multivariate analysis showed
that stage III gastric cancer patients with early recurrence had larger tumors and more lymph node metastasis,
coupled with aberrant expression EMT and cancer stem cell marker, than patients with late recurrence. Early
recurrence was associated with more distant metastasis than late recurrence and patients tended to die within
two years of recurrence.
Conclusions: Combined EMT with cancer stem cell-like marker is a predictor of recurrence after radical resection
for gastric cancer. Advanced TNM stage was associated with early cancer death after recurrence.Background
Gastric cancer is the fourth most common cancer in the
world, and surgery remains the main treatment, with
curative intent. Even after gastrectomy and lymphade-
nectomy, every year many patients die of recurrence.
The epithelial-mesenchymal transition (EMT), a devel-
opmental process in which epithelial cells show reduced
intercellular adhesion and acquire migratory fibroblastic
properties, is considered to be critical for invasive and
metastatic progression in cancer [1]. The process of* Correspondence: zhangweijie1616@163.com; zouxiaoping795@hotmail.com;
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unless otherwise stated.EMT is associated with the downregulation of epithelial
markers, abnormal translocation of β-catenin, and aber-
rant upregulation of mesenchymal markers. Cancer stem
cells are cells within a tumor that possess self-renewal
and tumor-initiating capacities. In gastric cancer, CD44-
positive tumor cells were shown to have cancer stem cell
properties, including the tumor-initiating ability [2], and
Chen et al. [3] showed that CD44 + CD54+ cells exhibit
cancer stem cell capabilities in gastric cancer tissues.
These tumor-initiating cells provide a reservoir that can
cause tumor recurrence after therapy [4].
Previously, Ryu et al. [5] showed that a combination of
EMT and stem cell-like phenotypes is an important pre-
dictor of aggressive biologic behavior of gastric cancer;
however, few studies currently have been investigating
EMT with cancer stem cell-like marker in gastric cancer
with recurrence and prognosis. The aim of the currentThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the predictors of time of recurrence and initial recur-
rence patterns of gastric cancer with early and late
recurrence, and find risk factors to predicate early recur-
rence after radical resection for gastric cancer. This
could help in the preoperative assessment of appropriate
therapeutic strategies and in providing more intensive
and tailored follow-up strategies for high-risk patients.
Methods
Patient selection
Between January 2001 and January 2008, excluding pa-
tients who were lost to follow-up or poor compliance, a
total of 1,463 patients underwent curative resection for
gastric cancer at Drum Tower Hospital. A total of 402
(27.5%) of these patients experienced recurrence and
were subsequently included in the study; thus the recur-
rence rate in our study was 27.5%. The mean age of the
402 patients was 64.7 years (range: 26 to 91 years), with
a male:female ratio of 1.87:1. Medical charts and path-
ology reports were reviewed to record clinical and
pathological data. To evaluate whether the expression
profiles of the various EMT markers were different be-
tween primary and metastatic gastric cancers, cases with
regional lymph node metastasis were also evaluated. In
terms of the timing of recurrence, some tumors recur
within the first year after resection, and in these cases,
inadequate radical surgical approach or systematic me-
tastasis at operation may be suspected. In our study, we
defined early recurrence as recurrence within two years
after surgery. Late recurrence was defined as recurrence
more than two years after surgery. These 402 patients
were divided into two groups, namely the early recur-
rence group, which contained 248 patients, and the late
recurrence group, which contained 154 patients. Exclu-
sion criteria included synchronous gastric double cancer,
a previous history of surgery for gastric cancer, gastric
stump cancer, or cancer anatomically classified as
esophageal cancer according to the American Joint
Committee on Cancer (AJCC) seventh edition [6].
The study was approved by the clinical research ethics
committees of the Drum Tower Hospital and informed
consent was obtained from all patients.
Tissue array and immunohistochemistry
All samples in the study were removed from formalin-
fixed paraffin-embedded gastric cancer tissues. For all of
the arrays, three cores from different areas of the tumor
in each case were removed and placed into a new blank
recipient paraffin block as previously described by Hsu
et al. [7], and 4-μm thick sections were obtained for im-
munohistochemistry. The specimens were deparaffinized
and dehydrated by a graded series of ethanol solutions
(Nanjing Chemical Reagent Co., Ltd., Nanjing, China).The immunohistochemical staining for EMT-related
proteins Snail-1, zinc finger E-box-binding homeobox 1
(ZEB-1), vimentin, E-cadherin, β-catenin, and cancer
stem cell-like markers CD44 and CD54, were performed
and evaluated according to the previous method [3,5].
As for statistical analysis of multiple markers, the spe-
cimen was recorded as having positive immunoreactivity
for each antibody, excluding E-cadherin, if more than
5% of the cancer cells were immunoreactive, and tumor
cells with less than 5% were considered as negative. The
scoring criteria for E-cadherin were defined as ‘positive
(intact)’ when immunoreactivity on the cell membrane
was present in more than 25% of the gastric cancer cells.
Patterns of recurrence
Patterns of recurrence reported represent the first sites of
documented recurring disease after curative resection. Re-
currence was documented from the first clinical or radio-
logical signs of disease with an unrelenting course leading
to tumor progression and/or death. Confirmation through
biopsy was recommended for any evidence of recurrent
disease or distant metastases. Recurrence patterns were
classified as locoregional, peritoneal, or hematogenous.
Locoregional recurrence was defined as any cancer recur-
rence at the resection margin or lymph nodes (including
regional nodes as well as retropancreatic and para-aortic
nodes) or operation bed within the region of the resection
(below the diaphragm and liver, and above the pancreas
and abdominal wound). Peritoneal recurrence was defined
as any cancer recurrence within the abdominal cavity due
to intraperitoneal distribution including visceral metasta-
sis, rectal shelf, pericholedochal, and periureteral infiltra-
tion. Hematogenous recurrence was defined as any
metastatic lesion detected in liver, lung, bone, and other
distant organs.
Follow-up
After surgery, all patients were followed up on regularly.
Follow-up assessments were performed every three
months for the first five years after surgery, and every
six months thereafter until the patient’s death. The
follow-up procedures included a medical history, phys-
ical examination, routine blood tests, liver function tests,
measurement of tumor marker levels (carcinoembryonic
antigen and carbohydrate antigen 199), a chest radio-
graph, and other imaging studies. All routine procedures
were performed by a surgeon, esophagogastroduodeno-
scopy was performed by a gastroenterologist, and upper
gastrointestinal series, abdominal sonogram, and com-
puted tomography (CT) scans were performed by a
radiologist. For confirmed recurrent disease or distant
metastases, biopsies were not obtained for new, multiple
pulmonary lesions or for lesions characteristic of osseous
metastases noted on CT or whole-body bone scans.
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utilized, such as bone scan, positron emission tomog-
raphy (PET), and biopsy sampling.
Statistical analysis
All values are expressed as the mean ± standard devi-
ation. Categorical variables were analyzed using the χ2
test and continuous variables using the independent-
samples t-test. Logistic regression multivariate analysis
was conducted to determine the differences between
the two groups. Analysis of survival was performed by
the Kaplan-Meier method, and differences between
the curves were tested using a two-tailed log-rank test.
P <0.05 was considered to be statistically significant.
Statistical analysis was performed using SPSS (SPSS 13.0
for Windows; SPSS Inc., Chicago, Illinois, United States)
software.
Results
Expression of epithelial-mesenchymal transition and
cancer stem cell-like marker association with tumor
recurrence
Table 1 shows the clinicopathologic characteristics of
the patients with early recurrence and late recurrence.
Among the perioperative variables recorded for univari-
ate analysis were: presence of CD44, CD54, and vimen-
tin, loss of E-cadherin and β-catenin expression, with a
tumor size of 5 cm or more, more advanced T-stage,
and a more advanced TNM stage with early recurrence
to late recurrence Multivariate analysis was employed to
identify the independent risk factors for overall recur-
rence. The analysis showed that patients presenting with
a tumor size of 5 cm or more, and a more advanced
TNM stage, coupled with EMT expression and expres-
sion of cancer stem cell marker CD44, were prominent
in early recurrence (Table 2).
Patterns of recurrence
The median time to recurrence was 17.0 months (range:
2.0 to 89.0). Most recurrences in our study group (248
out of 402, 61.7%) occurred within two years after cura-
tive surgery (Table 3). In the early recurrence group, the
most common pattern was hematogenous metastasis,
followed by locoregional and peritoneal recurrence. In-
cluding patterns that developed concurrently, locoregional
and hematogenous recurrence was the most common pat-
tern, followed by peritoneal recurrence. In the late recur-
rence group, the most common pattern was locoregional
and peritoneal recurrence, followed by hematogenous
recurrence as single patterns, and when patterns that
developed simultaneously were included, locoregional re-
currence was still the most common pattern. Distant
metastasis is more common in early recurrence, but peri-
toneal dissemination is not significant. Among patientswith hematogenous metastasis, liver metastasis is more
common in early recurrence.
Survival time after recurrence
The majority of patients with recurrence of gastric can-
cer (321 out of 402, 79.9%) died within two years after
recurrence. The median survival time after recurrence
was 8.1 months in early recurrence and 13.3 months in
late recurrence, respectively. A total of 16 patients sur-
vived more than five years after recurrence: 10 with early
recurrence and six with late recurrence. Among the 10
patients with early recurrence, the recurrence pattern in-
cluded one liver metastasis, two lung metastasis, three
anastomosis recurrences, two hepatoduodenal ligament
recurrences, one abdominal wall recurrence, and one
peritoneal seeding. Among the six patients with late
recurrence, the recurrence patterns included one ab-
dominal incision recurrence, two liver metastases, one
remnant stomach relapse, one hepatoduodenal ligament
recurrence, and one anastomosis recurrence with liver inva-
sion. Survival time after recurrence was significantly shorter
in the early group (P <0.001, log-rank test) (Figure 1).
Discussion
Gastric cancer represents the fourth leading cause of can-
cer mortality worldwide. Locoregional relapse may occur
after curative resection, including adjacent lymph nodes
resection and multidisciplinary treatment, possibly in the
form of peritoneal carcinosis and/or distant metastases,
which is one reason for the high rate of recurrence. Car-
cinoma relapse is essentially lethal, and so far there are no
specific treatments to avoid recurrence [8-10].
The clinical significance of EMT has been reported in
various human cancers, and specific mechanisms in-
volved in cancer progression, such as the evasion of
apoptosis, resistance to chemotherapy, and the acquisi-
tion of stem cell-like properties and their influence on
patient survival have been suggested [1,5,11,12]. CD44 is
a transmembrane glycoprotein that is well known as a
cancer stem cell marker in gastric cancer [2]. CD44 is
positively and significantly associated with tumor metas-
tasis, recurrence, and mortality in gastric cancer [13,14].
In the present study, expression of mesenchymal marker
vimentin was more frequent in early recurrence than in
late recurrence cancers (P <0.001), and E-cadherin expres-
sion was lost in 112 (45.2%) of 248 early recurrence can-
cers, but only 35 late recurrence (22.7%) cancers showed
loss of E-cadherin expression (P <0.001). These findings
demonstrate that the transformation of the gastric epithe-
lial cells could promote tumor recurrence and metastasis.
CD44 and CD54 expressions were also found more fre-
quently in early recurrence patients than those of late re-
currence (P = 0.001, P = 0.037), suggesting that stem cell
markers could be taken as a promoter for tumor progress.
Table 1 Clinicopathological characteristics of recurrent
gastric cancer patients
Early recurrence
(n = 248) n (%)
Late recurrence





Gender, male/female 162/86 100/54 0.937












Superficial tumor 18 25
Bormann type I and II 25 40





Intestinal type 104 69
Diffuse type 144 85






Depth of invasion <0.001
T1 and T2 46 53









Table 1 Clinicopathological characteristics of recurrent




Snail-1 117(47.2) 64(41.6) 0.271
ZEB-1 168(67.7) 109(70.8) 0.522
Vimentin 87(35.1) 21(13.6) <0.001
Expression loss of
epithelial marker
E-cadherin 112(45.2) 35 (22.7) <0.001
β-catenin 29 (11.7) 19(12.3) 0.846
Expression of cancer
stem cell marker (%)
CD44 163(65.7) 71(46.1) 0.001
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ity of the interactions between EMT-related proteins
and their effects on cancer recurrence. The present
study determined that the combination of alterations in
the protein expression of vimentin, E-cadherin, and
CD44 was the most effective prognostic factor in gastric
cancer. In addition, this combination was an independ-
ent predictive factor of recurrence, together with a con-
ventional clinicopathologic parameter such as pTNM
stage and histologic differentiation.
In our series, there is a large difference in cancer size,
gross appearance, lymph node metastasis, lymphovascular
invasion, depth of invasion, and stage between the early
and late recurrence groups, and patients with CD44 and
vimentin, and loss of E-cadherin and β-catenin expression,
have a higher tendency towards early recurrence. Our re-
sults showed that patients presenting with a tumor size of
5 cm or more, and a more advanced TNM stage, coupled
with EMT expression and expression of cancer stem cellTable 2 Multivariate analysis of factors independently
associated with the timing of recurrence (early versus late)




Tumor size ≥5 cm 172(69.4) 86(55.8) 0.001 8.750 (2.265 - 33.799)
TNM stage III 191(77.0) 68(44.2) 0.040 0.493 (0.251 - 0.970)
EMT expression (%)
Vimentin 87(35.1) 21(13.6) 0.031 2.359 (1.082 - 5.145)
E-cadherin 112(45.2) 35(22.7) <0.001 0.125 (0.046 - 0.338)
Expression of cancer
stem cell marker (%)
CD44 163(65.7) 71(46.1) 0.017 0.297 (0.108 - 0.806)
Table 3 The pattern of initial recurrence of gastric cancer
Early recurrence
(n = 248) n (%)
Late recurrence
(n = 154) n (%)
P value
Locoregional recurrence 161(64.9) 85(55.2) 0.052
Hepatoduodenal ligament 57(23.0) 37(24) 0.810
Perigastric area 25(10.1) 24(15.6) 0.101
Anastomosis 23(9.3) 15(9.7) 0.877
Remnant stomach 15(6) 12(7.8) 0.601
Peripancreatic area 12(4.8) 9(5.8) 0.660
Abdominal wall 10(4) 7(4.5) 0.804
Lymph node 51(20.6) 27(17.5) 0.455
Mixed 10(4) 3(1.9) 0.251
Distant metastasis 207(83.5) 109(70.8) 0.003
Peritoneal dissemination 106(42.7) 62(40.3) 0.624
Hematogenous metastasis 112(45.2) 49(31.8) 0.008
Liver 64(25.8) 23(14.9) 0.010
Lung 25(10.1) 17(11) 0.760
Bone 9(3.6) 4(2.6) 0.570
Adrenal gland 7(2.8) 3(1.9) 0.584
Brain 2(0.8) 0 0.264
Skin 2(0.8) 0 0.264
Mixed 3(1.2) 2(1.3) 0.938
Figure 1 Comparison of survival after recurrence by Kaplan-Meir.
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multivariate analysis.
As for recurrence patterns, in general, there are three
main recurrence patterns of gastric cancer after curative
surgery: locoregional recurrence, peritoneal dissemination,
and hematogenous metastasis. Our data showed that pa-
tients with early recurrence had more distant metastasis,
but not peritoneal dissemination, than those with late re-
currence. Hematogenous metastasis was more common in
early recurrence, which was similar to some studies [9,10].
There is no significant difference between early and late
recurrence with respect to locoregional recurrence. We
found that liver, lung, and bone are the most frequently
hematogenous metastatic organs. This result concurs with
others [10,15]. Liver metastases show a tendency to occur
earlier, whereas lung and bone metastases occur later. The
liver is the first filter of cancer cells through the portal
venous blood flow of the stomach; the lung functions as a
secondary filter. This result suggests that patients should
be monitored carefully for hematogenous metastasis dur-
ing the first two years of follow-up, and for locoregional or
peritoneal recurrence subsequently.
Survival times after recurrence have rarely been docu-
mented in previous studies, although a new study per-
formed by Wu et al. [16] reported that most patients
succumbed within one year of receiving a diagnosis of re-
currence, with the median survival time after recurrence
being only 6.7 months. In our results, the median survival
time of the early recurrence group was significantly lower
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after recurrence of cancer and an unfavorable response to
the chemotherapy in some patients, 16 patients had long-
term survival of more than five years after recurrence. We
suggest that close follow-up with B-ultrasound and endos-
copies are important, especially in the first two years, in
order to prolong survival.
Conclusions
Hematogenous metastasis was found to be common in
patients that experienced recurrence within two years of
curative resection, and patients with large tumor size
(≥5 cm) and advanced TNM stage (stage III) were found
to be more prone to early recurrence. EMT and stem cell-
like phenotypes are correlated with aggressive clinical
features in gastric cancer, and the three proteins, E-
cadherin, vimentin, and CD44, may be the best combin-
ation for predicting patient recurrence.
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